ATLANTA, July 13 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY),an
implantable biological medical device and cardiovascular tissue processing
company,announced today that 2009 second quarter financial results will be
released on Thursday, July 30, 2009. On that day, the Company will hold a
teleconference call and live webcast at 10:00 a.m. Eastern Time to discuss the
results, followed by a question and answer session hosted by Steven G.
Anderson, president and chief executive officer of CryoLife, Inc.
To listen to the live teleconference, please dial 201-689-8261 a few
minutes prior to 10:00 a.m. A replay of the teleconference will be available
July 30 through August 7 and can be accessed by calling (toll free)
877-660-6853 or 201-612-7415. The account number for the replay is 244 and
the conference number is 327576.
The live webcast and replay can be accessed by going to the Investor
Relations section of the CryoLife Web site at www.cryolife.com and selecting
the heading Webcasts & Presentations.
About CryoLife, Inc.
Founded in 1984, CryoLife, Inc. is a leader in the processing and
distribution of implantable living human tissues for use in cardiac and
vascular surgeries throughout the U.S. and Canada. The Company's CryoValve
SG pulmonary human heart valve, processed using CryoLife's proprietary
SynerGraft technology, has FDA 510(k) clearance for the replacement of
diseased, damaged, malformed or malfunctioning native pulmonary valves. The
Company's BioGlue Surgical Adhesive is FDA approved as an adjunct to sutures
and staples for use in adult patients in open surgical repair of large
vessels. BioGlue is also CE marked in the European Community and approved in
Canada and Australia for use in soft tissue repair. BIOGLUE Aesthetic(TM)
Medical Adhesive is CE marked in the European Community for periosteal
fixation following endoscopic browplasty (brow lift) in reconstructive plastic
surgery and is distributed by a third party for this indication. CryoLife
distributes HemoStase(TM), a hemostatic agent, in much of the U.S. for use in
cardiac and vascular surgery and in the European Community and Canada for
cardiac, vascular, and general surgery, subject to certain exclusions.
SOURCE CryoLife, Inc.
CONTACT: D. Ashley Lee, Executive Vice President, Chief Financial
Officer and Chief Operating Officer, +1-770-419-3355; or Katie Brazel,
Fleishman Hillard, +1-404-739-0150/
Web Site: http://www.cryolife.com
(CRY)
